Abstract 790P
Background
Endometrial carcinoma (EC) guidelines (NCCN, ESGO) suggest molecular analysis (MA) for incorporation into risk criteria. Prognostic value of TCGA-based classification has been validated, but adoption into adjuvant treatment decisions is still under evaluation. Examples of real-world upfront MA analysis in EC are scarce. We aim to evaluate our routine implementation of Next Generation Sequencing (NGS) of EC patients.
Methods
In November 2020, we implemented routine immunohistochemistry (IHC) (p53, MMR) & NGS for TCGA-based prognostication of all EC primary resections at a single institution. NGS was a 69 gene panel including POLE, TP53, PTEN, CTNNB1, KRAS, ERBB2, & PIK3CA. A questionnaire directed to treating oncologists evaluating impact of MA on adjuvant management decisions and counselling was utilized.
Results
189 patients amongst 7 treating gynecologic oncologists were evaluated over the initial 13 months. Primary stage of disease was; I: 139 (73.5%), II: 11(5.8%), III: 27 (14.3%), IV: 12 (6.4%). Prognostic classifiers were: POLE: 10 (5.3%); MMRd 52 (27.5%); NSMP: 86 (45.5%); and p53: 41 (21.7%), including multiple-classifiers: 10 (5.3%) MMRd-p53 and 4 (2.1%) POLE-p53. The classifiers with the most impact for providers were MMRd: 27 (14.3%) and p53: 22 (11.6%). Prognostic classification impacted patient counselling in 72 (38.1%) of patients (POLE 66.7%; MMRd 59.5%; p53 52.5%; NSMP 12.6%; p<0.001), with NSMP having the least impact. MA impacted treatment recommendations in 19 (10%) of patients. MA altered treatment recommendations compared to recommendations by histological properties in 8 (4.2%) patients. MA significantly impacted treatment recommendations with increasing stage (I: 5.8%, II: 9.1%, III: 22.2%, IV: 33.3%, p=0.002). MA significantly altered treatment recommendations deviating from histological recommendations with increasing stage (I: 1.4%, II: n/a, III: 14.8%, IV: 16.7%, p=0.002).
Conclusions
Comprehensive uniform molecular analysis of endometrial carcinoma via combined IHC and NGS upon primary resection is feasible and contributes to patient counseling and treatment recommendations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Colorado.
Funding
Has not received any funding.
Disclosure
B.R. Corr: Financial Interests, Institutional, Advisory Board: GSK, Gilead, Immunogen, Zentalis, Merck; Financial Interests, Institutional, Funding: Clovis, Immunogen. C. Walsh: Financial Interests, Institutional, Advisory Board: Immunogen, Regeneron. L. Brubaker: Financial Interests, Institutional, Advisory Board: AstraZeneca. S.R. Guntupalli: Financial Interests, Institutional, Advisory Board: Seagen. D. Aisner: Financial Interests, Institutional, Funding: Takeda, Loxo Oncology, Eli Lily, Sanofi Genzyme, AstraZeneca, Genentech, AbbVie, Janssen. All other authors have declared no conflicts of interest.
Resources from the same session
812P - Mental and socioeconomic burden in co-parents and children of patients with endometrial and cervical cancer: A Swedish population-based study
Presenter: Karin Sundström
Session: Poster session 11
814P - Clinical significance of isolated pulmonary recurrence in patients with endometrioid endometrial cancer who achieved complete remission after primary treatment
Presenter: Jigeun Yoo
Session: Poster session 11
815P - Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study
Presenter: Jerome Alexandre
Session: Poster session 11
816P - Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
Presenter: Alain Zeimet
Session: Poster session 11
817P - A systematic review of recruitment of ethnic minorities to RCTs of systemic anti-cancer therapies in gynaecological cancers
Presenter: Luke Steventon
Session: Poster session 11